ROBIN FORDHAM: Open Payments
NPI 1902175276 · ORANGE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$330 in 14 payments from 8 companies in 2025. Trend: 2023 $1,039 · 2024 $887 · 2025 $330
Food & beverage: $330
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 4 | $93 |
| Amgen Inc. | 3 | $58 |
| Merck Sharp & Dohme LLC | 2 | $50 |
| Janssen Pharmaceuticals, Inc | 1 | $40 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $31 |
| Novartis Pharmaceuticals Corporation | 1 | $25 |
| SCPHARMACEUTICALS INC. | 1 | $18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $15 |
Products named: VRAYLAR, REPATHA, SPRAVATO, CAPLYTA, VERQUVO, LEQVIO, FUROSCIX, JARDIANCE.
Industry payments across CA — which companies pay providers there.
